News
July 7, 2021
Scorpion Therapeutics Announces New CEO Axel Hoos, M.D., Ph.D.
BOSTON, MA. — July 7, 2021 — Scorpion Therapeutics, Inc., a next-generation oncology company developing best- and first-in-class precision medicines for cancer patients, today announced that...Boston, MA | April 8, 2021
Scorpion Therapeutics Appoints Guy Padbury, Ph.D. as Chief Development Officer
BOSTON — April 8, 2021 — Scorpion Therapeutics, Inc., a next-generation precision oncology company, today announced the appointment of Guy Padbury, Ph.D. as Chief Development Officer....February 25, 2021
Scorpion Therapeutics Announces Leadership Change
– Board Appoints Adam Friedman, M.D., Ph.D., as Interim CEO – Scorpion Therapeutics announced that Adam Friedman, M.D., Ph.D., has been appointed Chief Executive Officer on an interim basis. The Board of Directors is currently evaluating...IN THE MEDIA
STAT (Subscription Required) | July 9, 2021
Scorpion Therapeutics hired Axel Hoos as chief executive officer. Previously, he worked at GlaxoSmithKline, where he was senior vice president of R&D governance chair and therapeutic area...Boston Business Journal | July 9, 2021
Just eight months out of stealth, precision medicine startup Scorpion Therapeutics has netted a big fish in Axel Hoos, the head of oncology at GlaxoSmithKline plc,...Scrip (Subscription Required) | July 7, 2021
Axel Hoos will become the CEO of a Boston-based cancer start-up focusing on targeted precision drugs. He talked to Scrip about the decision to leave GSK after 10...BioCentury (Subscription Required) | July 7, 2021
GSK is losing one of the principal architects of its oncology renaissance as immuno-oncology pioneer Axel Hoos prepares to leave the company for his first CEO...Fierce Biotech | July 7, 2021
After leading oncology teams at GlaxoSmithKline and Bristol Myers Squibb, Axel Hoos, M.D., Ph.D., is heading back to biotech.Endpoints | July 7, 2021
Axel Hoos has long kept the flame alive at GlaxoSmithKline’s oncology division, enduring lean days after the British pharma ditched its late-stage pipeline to Novartis and...Fierce Biotech | January 12, 2021
Less than three months after breaking cover with an impressive $102 million series A, Scorpion has whipped up another major funding round, nabbing $162 million for its next-gen cancer drugs.Boston Globe | January 12, 2021
Just over two months after announcing its debut with $108 million in funding, Boston startup Scorpion Therapeutics said Thursday it has raised an even larger amount of venture capital.Endpoints News | January 12, 2021
Whatever investors have peeped about Gary Glick and Keith Flaherty’s game plan to bring about Precision Oncology 2.0, it’s good enough for a $162 million infusion into Scorpion Therapeutics just weeks after its $108 million Series A.Fierce Biotech | October 26, 2020
When Gary Glick, Ph.D., left the CEO post at IFM Therapeutics, he didn’t know what was next. But he soon found himself on a plane with Loxo Oncology co-founder Keith Flaherty, and they got to talking about how they could “expand the boundaries of targeted oncology.”Events
Investor Contact
Hannah Deresiewicz
Stern Investor Relations, Inc.
hannah.deresiewicz@sternir.com
212-362-1200
Media Contact
Ravi Moorthy
ravi@scorpiontx.com